Growth in incidence of chronic kidney diseases is fueling the chronic kidney disease (CKD) drugs market size. Commonly used CKD medicines include calcium acetate and calcium carbonate.
Approval and launch of new drugs is propelling the chronic kidney disease (CKD) drugs market development. SGLT-2 inhibitors have shown potential in reducing the risk of kidney failure in randomized clinical trials. Medicines in the SGLT2 inhibitor class include canagliflozin, dapagliflozin, and empagliflozin.
Key players in the global market are focusing on innovative medicines and significantly expanding their renal portfolio, complementing the existing pipeline.
Chronic Kidney Disease (CKD) is characterized by the gradual loss of kidney function. Damaged kidneys are not able to filter the blood properly. There are five stages of kidney disease based on the presence of kidney damage and glomerular filtration rate (GFR), which is a measure of kidney function.
These stages include kidney damage (e.g., protein in the urine), kidney damage with a mild decrease in GFR, a moderate decrease in GFR, a severe reduction in GFR, and kidney failure.
Chronic Kidney Disease (CKD) drugs include Angiotensin-converting Enzyme (ACE) inhibitors, Angiotensin-II Receptor Blockers (ARBs), Calcium Channel Blockers (CCBs), beta blockers, erythropoiesis-stimulating agents, and diuretics.
ACE inhibitors and ARBs are two types of oral prescription medicines commonly recommended for people with CKD. CCBs are used to manage hypertension which is highly prevalent among people with the disease.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
High incidence of CKD, diabetes-related nephropathy, and hypertension-induced renal disorders are boosting demand for CKD drugs. Lifestyle factors, dietary habits, and genetic predispositions significantly impact the prevalence of chronic diseases related to kidneys.
More than 1 in 7 US adults-about 35.5 million people, or 14%-are estimated to have CKD, according to the Chronic Kidney Disease in the United States, 2023 Report by Centers for Disease Control and Prevention (CDC). Thus, high prevalence of CKD is fueling the chronic kidney disease (CKD) drugs market value.
Delaying disease progression and reducing the risk of mortality are key goals in the treatment of CKD. People with type 2 diabetes are at high risk of developing CKD. Semaglutide - sold under the brand name Ozempic - helps improve blood glucose (sugar) control in people with diabetes.
In March 2024, Novo Nordisk announced the headline results of their latest trial. The results suggest that semaglutide can reduce the risk of kidney disease progression by 24% in people who have type 2 diabetes and CKD. Thus, R&D in kidney disease progression is expected to spur the chronic kidney disease (CKD) drugs market growth in the near future.
Sodium-glucose Cotransporter-2 (SGLT2) inhibitors are effective at slowing the progression of kidney disease. They reduce heart failure and lower the risk of kidney failure and death in people with CKD and type 2 diabetes. Approval and launch of SGLT2 inhibitors is boosting the chronic kidney disease (CKD) drugs market revenue.
In September 2023, the U.S. Food and Drug Administration (FDA) approved Jardiance (empagliflozin) 10 mg tablets to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death, and hospitalization in adults with CKD at risk of progression.
The approval was based on the EMPA-KIDNEY trial designed to reflect the broad range of adults with CKD with or without type 2 diabetes. EMPA-KIDNEY is the first SGLT2 inhibitor CKD trial to demonstrate a statistically significant reduction in the risk of first and recurrent hospitalization in adults with CKD.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
According to the latest chronic kidney disease (CKD) drugs market analysis, North America held largest share in 2023. As per the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), 37 million people in the U.S. have kidney disease, which is more than 1 in 7 adults in the country. Thus, rise in prevalence of CKD is fueling the chronic kidney disease (CKD) drugs industry share in North America.
Key players operating in the chronic kidney disease (CKD) drugs market landscape are developing new treatment options to further improve the management of cardiorenal metabolic syndrome and renal disease.
F. Hoffmann-La Roche Ltd., Pfizer, Inc., Sanofi, GSK plc, Kissei Pharmaceutical Co., Ltd., AbbVie Inc., Akebia Therapeutics, Inc., AstraZeneca, Amgen Inc., and Teva Pharmaceutical Industries Ltd. are key players in the chronic kidney disease (CKD) drugs industry.
These companies have been profiled in the chronic kidney disease (CKD) drugs market report based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 14.8 Bn |
| Market Forecast (Value) in 2034 | US$ 23.8 Bn |
| Growth Rate (CAGR) | 4.2% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 14.8 Bn in 2023
It is projected to grow at a CAGR of 4.2% from 2024 to 2034
Growth in incidence of chronic kidney diseases and approval and launch of new drugs
North America was the dominant region in 2023
F. Hoffmann-La Roche Ltd., Pfizer, Inc., Sanofi, GSK plc, Kissei Pharmaceutical Co., Ltd., AbbVie Inc., Akebia Therapeutics, Inc., AstraZeneca, Amgen Inc., and Teva Pharmaceutical Industries Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Chronic Kidney Disease (CKD) Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2020-2034
6.3.1. ACE Inhibitors
6.3.2. Angiotensin-II Receptor Blockers
6.3.3. Calcium Channel Blockers
6.3.4. Beta Blockers
6.3.5. Erythropoiesis-stimulating Agents (ESAs)
6.3.6. Diuretics
6.3.7. Others
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by End-user, 2020-2034
7.3.1. Hospitals
7.3.2. Specialty Clinics
7.4. Market Attractiveness Analysis, by End-user
8. Global Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2020-2034
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Drug Class, 2020-2034
9.3.1. ACE Inhibitors
9.3.2. Angiotensin-II Receptor Blockers
9.3.3. Calcium Channel Blockers
9.3.4. Beta Blockers
9.3.5. Erythropoiesis-stimulating Agents (ESAs)
9.3.6. Diuretics
9.3.7. Others
9.4. Market Value Forecast, by End-user, 2020-2034
9.4.1. Hospitals
9.4.2. Specialty Clinics
9.5. Market Value Forecast, by Country, 2020-2034
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Drug Class
9.6.2. By End-user
9.6.3. By Country
10. Europe Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Class, 2020-2034
10.3.1. ACE Inhibitors
10.3.2. Angiotensin-II Receptor Blockers
10.3.3. Calcium Channel Blockers
10.3.4. Beta Blockers
10.3.5. Erythropoiesis-stimulating Agents (ESAs)
10.3.6. Diuretics
10.3.7. Others
10.4. Market Value Forecast, by End-user, 2020-2034
10.4.1. Hospitals
10.4.2. Specialty Clinics
10.5. Market Value Forecast, by Country/Sub-region, 2020-2034
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Italy
10.5.5. Spain
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By End-user
10.6.3. By Country/Sub-region
11. Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Class, 2020-2034
11.3.1. ACE Inhibitors
11.3.2. Angiotensin-II Receptor Blockers
11.3.3. Calcium Channel Blockers
11.3.4. Beta Blockers
11.3.5. Erythropoiesis-stimulating Agents (ESAs)
11.3.6. Diuretics
11.3.7. Others
11.4. Market Value Forecast, by End-user, 2020-2034
11.4.1. Hospitals
11.4.2. Specialty Clinics
11.5. Market Value Forecast, by Country/Sub-region, 2020-2034
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By End-user
11.6.3. By Country/Sub-region
12. Latin America Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Class, 2020-2034
12.3.1. ACE Inhibitors
12.3.2. Angiotensin-II Receptor Blockers
12.3.3. Calcium Channel Blockers
12.3.4. Beta Blockers
12.3.5. Erythropoiesis-stimulating Agents (ESAs)
12.3.6. Diuretics
12.3.7. Others
12.4. Market Value Forecast, by End-user, 2020-2034
12.4.1. Hospitals
12.4.2. Specialty Clinics
12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By End-user
12.6.3. By Country/Sub-region
13. Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Class, 2020-2034
13.3.1. ACE Inhibitors
13.3.2. Angiotensin-II Receptor Blockers
13.3.3. Calcium Channel Blockers
13.3.4. Beta Blockers
13.3.5. Erythropoiesis-stimulating Agents (ESAs)
13.3.6. Diuretics
13.3.7. Others
13.4. Market Value Forecast, by End-user, 2020-2034
13.4.1. Hospitals
13.4.2. Specialty Clinics
13.5. Market Value Forecast, by Country/Sub-region, 2020-2034
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By End-user
13.6.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2023)
14.3. Company Profiles
14.3.1. F. Hoffmann-La Roche Ltd.
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.2. Pfizer, Inc.
14.3.2.1. Company Overview
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Financial Overview
14.3.2.5. Strategic Overview
14.3.3. Sanofi
14.3.3.1. Company Overview
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Financial Overview
14.3.3.5. Strategic Overview
14.3.4. GSK plc
14.3.4.1. Company Overview
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Financial Overview
14.3.4.5. Strategic Overview
14.3.5. Kissei Pharmaceutical Co., Ltd.
14.3.5.1. Company Overview
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Financial Overview
14.3.5.5. Strategic Overview
14.3.6. AbbVie Inc.
14.3.6.1. Company Overview
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Financial Overview
14.3.6.5. Strategic Overview
14.3.7. Akebia Therapeutics, Inc.
14.3.7.1. Company Overview
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Financial Overview
14.3.7.5. Strategic Overview
14.3.8. AstraZeneca
14.3.8.1. Company Overview
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Financial Overview
14.3.8.5. Strategic Overview
14.3.9. Amgen Inc.
14.3.9.1. Company Overview
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Financial Overview
14.3.9.5. Strategic Overview
14.3.10. Teva Pharmaceutical Industries Ltd.
14.3.10.1. Company Overview
14.3.10.2. Product Portfolio
14.3.10.3. SWOT Analysis
14.3.10.4. Financial Overview
14.3.10.5. Strategic Overview
List of Tables
Table 01: Global Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
Table 02: Global Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2020-2034
Table 03: Global Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Region, 2020-2034
Table 04: North America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Country, 2020-2034
Table 05: North America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
Table 06: North America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2020-2034
Table 07: Europe Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 08: Europe Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
Table 09: Europe Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2020-2034
Table 10: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 11: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
Table 12: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2020-2034
Table 13: Latin America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Latin America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
Table 15: Latin America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2020-2034
Table 16: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 17: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
Table 18: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2020-2034
List of Figures
Figure 01: Global Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2034
Figure 02: Global Chronic Kidney Disease (CKD) Drugs Market Revenue (US$ Mn), by Drug Class, 2023
Figure 03: Global Chronic Kidney Disease (CKD) Drugs Market Value Share, by Drug Class, 2023
Figure 04: Global Chronic Kidney Disease (CKD) Drugs Market Revenue (US$ Mn), by End-user, 2023
Figure 05: Global Chronic Kidney Disease (CKD) Drugs Market Value Share, by End-user, 2023
Figure 06: Global Chronic Kidney Disease (CKD) Drugs Market Value Share, by Region, 2023
Figure 07: Global Chronic Kidney Disease (CKD) Drugs Market Value (US$ Mn) Forecast, 2020-2034
Figure 08: Global Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 09: Global Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 10: Global Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by End-user, 2023 and 2034
Figure 11: Global Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by End-user, 2024-2034
Figure 12: Global Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Region, 2023 and 2034
Figure 13: Global Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Region, 2024-2034
Figure 14: North America Chronic Kidney Disease (CKD) Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 15: North America Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Country, 2024-2034
Figure 16: North America Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Country, 2023 and 2034
Figure 17: North America Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 18: North America Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by End-user, 2023 and 2034
Figure 19: North America Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 20: North America Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by End-user, 2024-2034
Figure 21: Europe Chronic Kidney Disease (CKD) Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 22: Europe Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 23: Europe Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 24: Europe Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 25: Europe Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by End-user, 2023 and 2034
Figure 26: Europe Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 27: Europe Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by End-user, 2024-2034
Figure 28: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 29: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 30: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 31: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 32: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by End-user, 2023 and 2034
Figure 33: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 34: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by End-user, 2024-2034
Figure 35: Latin America Chronic Kidney Disease (CKD) Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 36: Latin America Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 37: Latin America Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 38: Latin America Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 39: Latin America Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by End-user, 2023 and 2034
Figure 40: Latin America Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 41: Latin America Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by End-user, 2024-2034
Figure 42: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 43: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 44: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 45: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 46: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by End-user, 2023 and 2034
Figure 47: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 48: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by End-user, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Chronic Kidney Disease (CKD) Drugs Market
*86 figures and 60 tables includes